CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Johnson & Johnson

JNJ
$352.00B
Mega Cap
NYSEPharmaceutical PreparationsPharmaceutical🇺🇸North AmericaNEW BRUNSWICK138.1K employees

Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest United States corporations. In 2024, the company was ranked 45th in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 138,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato. Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA.

Website

Drugs in Pipeline

163

Phase 3 Programs

111

Upcoming Catalysts

2

Next Catalyst

Mar 9, 2026

29d
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 1 past

Phase 2Next

Dupilumab Phase 2 Results Expected

Mar 9, 2026Dupilumab256

Primary completion for Dupilumab trial (NCT06881251) in Dermatitis, Atopic

Source
Phase 3

JNJ-90301900 (NBTXR3) Phase 3 Results Expected

Jun 30, 2026JNJ-90301900 (NBTXR3)500

Primary completion for JNJ-90301900 (NBTXR3) trial (NCT04892173) in Locally Advanced Head and Neck Squamous Cell Carcinoma

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Tapentadol (CG5503) Extended Release (ER)

Phase 3

Pain

norelgestromin + ethinyl estradiol; triphasil.

Phase 3

Contraception

doripenum

Phase 3

Urinary Tract Infections

acetaminophen extended release

Phase 3

Osteoarthritis

CG5503

Phase 3

Diabetic Neuropathy

Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)

Phase 3

Chronic Pain

CG5503 IR; tapentadol

Phase 3

Osteoarthritis

tramadol, acetaminophen

Phase 3

Diabetic Neuropathies

5% Minoxidil

Phase 3

Alopecia

naproxen

Phase 3

Osteoarthritis, Hip

risperidone; quetiapine

Phase 3

Bipolar Disorder

minoxidil

Phase 3

Androgenetic Alopecia

PDE5I (phosphodiesterase-5 inhibitor)

Phase 3

Erectile Dysfunction

Extended Release OROS® Paliperidone

Phase 3

Schizophrenia

acetaminophen Tablet

Phase 3

Post Operative Dental Pain

Paliperidone

Phase 3

Schizophrenia

Tipifarnib;Zarnestra; R115777

Phase 3

Acute Myeloid Leukemia

Epoetin alfa 3 times weekly /once weekly

Phase 3

Anemia

epoetin alfa

Phase 3

Chronic Kidney Disease

Risperidone long-acting injectable

Phase 3

Schizophrenia

Prucalopride

Phase 3

Constipation

topiramate, propranolol

Phase 3

Migraine

Ibrutinib

Phase 3

Leukemia, Lymphocytic, Chronic, B-Cell

TAR-200

Phase 3

Non-Muscle Invasive Bladder Neoplasms

Levetiracetam

Phase 3

Epilepsy

Cilta-cel

Phase 3

Multiple Myeloma

TMC435

Phase 3

Hepatitis C

Risperidone Long-acting Injectable (LAI) 25 mg

Phase 3

Schizophrenia

Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)

Phase 3

Chronic Pain

JNJ-77242113

Phase 3

Plaque Psoriasis

Simeprevir

Phase 3

Hepatitis C Virus Infection

Fentanyl

Phase 3

Postherpetic Neuralgia

No treatment

Phase 3

Hepatitis C

JNJ-63723283

Phase 3

Multiple Myeloma

Guselkumab

Phase 3

Psoriasis

Daratumumab

Phase 3

Multiple Myeloma

Fulranumab 1 mg

Phase 3

Osteoarthritis

Ad26.COV2.S

Phase 3

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

Macitentan

Phase 3

Pulmonary Arterial Hypertension

Sirukumab 100 mg

Phase 3

Arthritis, Rheumatoid

Seltorexant

Phase 3

Depressive Disorder, Major

Ustekinumab

Phase 3

Crohn Disease

Teclistamab

Phase 3

Multiple Myeloma

Ustekinumab 90 mg SC q8w

Phase 3

Crohn's Disease

Group 1: Epoetin alfa

Phase 3

Myelodysplastic Syndromes

Lazertinib

Phase 3

Carcinoma, Non-Small-Cell Lung

PP6M

Phase 3

Schizophrenia

Etravirine

Phase 3

HIV Infections

Risperidone, long-acting injectable

Phase 3

Schizophrenia

Tapentadol (CG5503)

Phase 3

Arthralgia

Quetiapine

Phase 3

Bipolar Disorder

Durogesic® (fentanyl transdermal drug delivery system)

Phase 3

Chronic Pain

galantamine ER

Phase 3

Alzheimer's Disease

Test acetaminophen

Phase 3

Post-operative Dental Pain

risperidone oral tablets

Phase 3

Anxiety Disorders

Doxorubicin

Phase 3

Sarcoma

CG 5503;tapentadol

Phase 3

Osteoarthritis

tapentadol (CG5503) ER

Phase 3

Low Back Pain

levofloxacin

Phase 3

Pneumonia

Rivaroxaban

Phase 3

Atrial Fibrillation

tapentadol (CG5503) Immediate Release IR

Phase 3

Low Back Pain

levofloxacin, azithromycin, amoxicillin/clavulanate

Phase 3

Bronchitis

Acetaminophen/Naproxen Sodium Fixed Combination

Phase 3

Pain

Bortezomib

Phase 3

Multiple Myeloma

Paliperidone extended-release

Phase 3

Bipolar Disorder

Risperdal Consta

Phase 3

Bipolar Disorder

Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)

Phase 3

Multiple Myeloma

paliperidone ER Oros

Phase 3

Schizophrenia

Gemcitabine with R115777

Phase 3

Pancreatic Neoplasms

Mebendazole

Phase 3

Healthy Volunteers

Dapoxetine

Phase 3

Erectile Dysfunction

F# 13418-148 Eye Drops

Phase 3

Ophthalmic Solutions

Rivaroxaban 2.5 mg

Phase 3

Acute Coronary Syndrome

Dexamethasone

Phase 3

Endometrial Neoplasms

levofloxacin; amoxicillin/clavulanate

Phase 3

Otitis Media

Paliperidone ER

Phase 3

Schizophrenia

topiramate

Phase 3

Essential Tremor

doripenem

Phase 3

Pneumonia

Trabectedin

Phase 3

Ovarian Cancer

risperidone

Phase 3

Bipolar Disorders

norelgestromin + ethinyl estradiol

Phase 3

Contraception

Rabeprazole sodium 5 mg

Phase 3

Gastroesophageal Reflux

Tapentadol extended release (ER)

Phase 3

Diabetic Peripheral Neuropathy

Oxycodone CR

Phase 3

Osteoarthritis, Hip

oxycodone IR

Phase 3

Joint Diseases

Thalidomide

Phase 3

Multiple Myeloma

oxycodone

Phase 3

Osteoarthritis, Knee

Paliperidone ER OROS®

Phase 3

Schizophrenia

CG5503 IR;tapentadol

Phase 3

Arthralgia

Topiramate; Carbamazepine; Valproate

Phase 3

Epilepsy

levofloxacin; imipenem/cilastitin

Phase 3

Nosocomial Pneumonia

Pancrease MT 10.5, or MT 21

Phase 3

Exocrine Pancreatic Insufficiency

Colloidal Oatmeal Cream

Phase 3

Eczema

ivermectin

Phase 3

Lice Infestations

Paliperidone palmitate 25 mg eq.

Phase 3

Schizophrenia

JNJ-90301900 (NBTXR3)

Phase 3

Locally Advanced Head and Neck Squamous Cell Carcinoma

norelgestromin + ethinyl estradiol; mercilon

Phase 3

Contraception

Extended-release galantamine hydrobromide

Phase 3

Schizophrenia

acetaminophen

Phase 3

Osteoarthritis of the Knee

Olanzapine

Phase 3

Bipolar Disorder

Risperidone, oral tablets

Phase 3

Bipolar Disorders

Test naproxen sodium tablet

Phase 3

Post-operative Dental Pain

galantamine

Phase 3

Alzheimer's Disease

5% Minoxidil Topical Foam

Phase 3

Androgenetic Alopecia

Imonogas

Phase 3

Functional Dyspepsia

rabeprazole

Phase 3

Gastroesophageal Reflux Disease (GERD)

galantamine hydrobromide

Phase 3

Alzheimer Disease

Hydromorphone HCl

Phase 3

Pain

topiramate, phenytoin

Phase 3

Epilepsy

Paliperidone palmitate

Phase 3

Schizophrenia

Docetaxel

Phase 3

Breast Cancer

R228060

Phase 2

Major Depressive Disorder

Atomoxetine 80 mg/d

Phase 2

Attention Deficit Hyperactivity Disorder

Lenalidomide

Phase 2

Lymphoma, Mantle-Cell

JNJ 40929837

Phase 2

Asthma

Investigational Lubricating Eye Drop in a Novelia® bottle

Phase 2

Dry Eye

R209130

Phase 2

Schizophrenia

JNJ-90301900

Phase 2

Carcinoma, Non-Small-Cell Lung

Experimental Product 1% Colloidal Oatmeal Balm

Phase 2

Atopic Dermatitis

JNJ-39220675

Phase 2

Allergic Rhinitis

JNJ16269110

Phase 2

Diabetes Mellitus, Type 2

Abiraterone acetate

Phase 2

Prostate Neoplasms

ibuprofen; pseudoephedrine HCl

Phase 2

Enuresis

Decitabine

Phase 2

Myelodysplastic Syndrome

Yondelis

Phase 2

Liposarcoma

R256918

Phase 2

Obesity

Acetaminophen/naproxen sodium Dose A

Phase 2

Pain

ZARNESTRA, tipifarnib, R115777

Phase 2

Acute Myeloid Leukemia

Amivantamab

Phase 2

Carcinoma, Non-Small-Cell Lung

Canagliflozin 50 mg

Phase 2

Diabetes Mellitus, Type 2

Apalutamide

Phase 2

Salivary Gland Neoplasms

VX-787 300 mg

Phase 2

Influenza A

tapentadol HCl

Phase 2

Pain

JNJ-73763989

Phase 2

Hepatitis B, Chronic

JNJ-17166864

Phase 2

Allergic Rhinitis

JNJ-37822681

Phase 2

Schizophrenia

Acetaminophen (ACE) (1000 mg)

Phase 2

Dental Pain

Ad26.Mos.HIV

Phase 2

Healthy

ET743

Phase 2

Breast Neoplasms

Canagliflozin (JNJ-28431754)

Phase 2

Diabetes Mellitus, Type II

RWJ-445380 100 mg

Phase 2

Rheumatoid Arthritis

Escitalopram

Phase 2

Major Depressive Disorder

R092670

Phase 2

Schizophrenia

PROCRIT (Epoetin alfa)

Phase 2

Anemia

NNC0142-0002

Phase 2

Inflammation

RSV Vaccine

Phase 2

Healthy

Olomorasib

Phase 2

Carcinoma, Non-Small-Cell Lung

Ad26.RSV.preF

Phase 2

Respiratory Syncytial Virus

JNJ-41443532

Phase 2

Diabetes Mellitus, Type 2

Tapentadol

Phase 2

Pain

Rilpivirine

Phase 2

HIV-1

Blink® Tears eye drops in a multidose bottle

Phase 2

Visual Acuity

JNJ-39588146 5 ng/kg/min

Phase 2

Heart Failure

tipifarnib (R115777)

Phase 2

Leukemia, Nonlymphocytic, Acute

JNJ39758979

Phase 2

Asthma

Dupilumab

Phase 2

Dermatitis, Atopic

Abiraterone

Phase 2

Prostate Cancer

Talquetamab

Phase 2

Multiple Myeloma

Erdafitinib

Phase 2

Advanced Solid Tumor

440 mg naproxen sodium with 1000 mg acetaminophen

Phase 2

Pain

Imipenem/cilastatin

Phase 2

Pneumonia, Ventilator-Associated

JNJ-31001074

Phase 2

Attention Deficit Hyperactivity Disorder

JNJ-26489112

Phase 2

Photosensitive Epilepsy

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals
JNJ News